Other languages IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Delayed OTC Markets Other stock markets 01:27:54 17/05/2024 am IST			5-day change	1st Jan Change
0.167 ^USD	-3.75%		-.--%	+20.93%

11/06	IntelGenx Reports Launch of Sale and Investment Solicitation Process	MT
28/05	IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

IntelGenx Technologies Corp. Announces Board Resignations	17/05
IntelGenx Technologies Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	17/05
IntelGenx Technologies Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	21/03
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats	05/02
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	18/12
IntelGenx Technologies Corp. Announces Changes to its Board of Directors	04/12
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	14/11
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	14/11
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Intelgenx Technologies Corp. Announces Co-Development and Commercialization of Cannabinoid-Infused Versafilm® Products with Tilray	06/11
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States	26/23/26
Intelgenx Corp. Receives the First Purchase Order for Rizafilm	21/23/21
IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film	19/23/19
IntelGenx Closes First Tranche of Private Placement From Strategic Partner For Aggregate Proceeds of US$3 Million	31/23/31
Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Other languages

Filters